Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients

Journal of Diabetes and its Complications

Volumn 29, Issue 8, 2015, Pages 1165-1170

  Nekaies, Ymène ^a   Baudin, Bruno ^b   Kelbousi, Sami ^c   Sakly, Mohsen ^a   Attia, Nebil ^a  

^a University of Carthage   (Tunisia)

^b Universite Paris Sud   (France)

^c Regional Hospital of Bizerte   (Tunisia)

Author keywords

Dyslipidemia; LDL receptor; Lp(a); Proprotein convertase subtilisin kexin type 9; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RECOMBINANT PROTEIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LDLR PROTEIN, HUMAN; LIPID; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADULT; BLOOD; COHORT ANALYSIS; COMPLICATION; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; TUNISIA; UPREGULATION;

ADULT; AGED; BIOMARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RISK FACTORS; SERINE ENDOPEPTIDASES; TUNISIA; UP-REGULATION;

EID: 84948670969     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.08.003     Document Type: Article

References (54)

1. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, and M. Devillers C. Boileau Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nature Genetics 34 2003 154 156
2. W.E. Alborn, G. Cao, H.E. Careskey, Y.W. Qian, D.R. Subramaniam, and J. Davies R.J. Konrad Serum proprotein convertase subtilisin/kexin type 9 is correlated directly with serum LDL cholesterol Clinical Chemistry 53 2007 1814 1819
3. A. Attia, V. Durlach, J.L. Paul, T. Soni, D. Betoulle, and A. Girard-Globa Modulation of low density lipoprotein subclasses by alimentary lipemia in control and normo-triglyceridemic non-insulin-dependent diabetic subjects Atherosclerosis 113 1995 197 209
4. A. Baass, G. Dubuc, M. Tremblay, E.E. Delvin, J. O'loughlin, and E. Levy M. Lambert Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents Clinical Chemistry 55 2009 1637 1645
5. H. Ben Romdhane, S. Ben Ali, W. Aissi, P. Traissac, H. Aounallah-Skhiri, and S. Bougatef N. Achour Prevalence of diabetes in Northern African countries: The case of Tunisia BMC Public Health 14 2014 86 98
6. R. Bouguerra, H. Alberti, L. Ben Salem, C. Ben Rayana, J. El Atti, and S. Gaigi K. Alberti The global diabetes pandemic: The Tunisian experience European Journal of Clinical Nutrition 61 2007 160 165
7. M.C. Brouwers, J.S. Troutt, M.M. Van Greeven broek, I. Ferreira, E.J. Feskens, and C.J. Van der Kallen C.D. Stehouwer Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study Atherosclerosis 217 2011 263 267
8. M. Burstein, H.R. Scholnick, and R. Morfin Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions Journal of Lipid Research 11 1970 583 595
9. G. Cazzolato, G. Prakash, S. Green, and G.M. Kostner The determination of lipoprotein Lp(a) by rate endpoint nephelemetry Clinica Chimica Acta 135 1983 203 208
10. R. Chaaba, N. Attia, S. Hammami, M. Smaoui, K. Ben Hamda, and S. Mahjoub M. Hammami Association between apolipoprotein E polymorphism, lipids, and coronary artery disease in Tunisian type 2 diabetes Journal of Clinical Lipidology 2 2008 360 364
11. D.C. Chan, G. Lambert, P.H. Barrett, K.A. Rye, E.M. Ooi, and G.F. Watts Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism? Clinical Chemistry 55 11 2009 2049 2052
12. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1 1976 31 41
13. J.C. Cohen, E. Boerwinkle, T.H. Mosley, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease New England Journal of Medicine 354 2006 1264 1272
14. Q. Cui, X. Ju, T. Yang, M. Zhang, W. Tang, and Q. Chen G. Cao Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population Atherosclerosis 213 2010 632 636
15. G.H. Dahlen, J.R. Guyton, M. Attar, J.A. Farmer, J.A. Kautz, and A.M. Gotto Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography Circulation 74 1986 758 765
16. N.R. Dessai, P. Kohli, R.P. Giugliano, M.L. O'Donoghue, R. Somaratne, and J. Zhou M.S. Sabatine AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE) - Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation 128 9 2013 962 969
17. L. Duvillard, E. Florentin, G. Lizard, J.M. Petit, F. Galland, and S. Monier B. Vergès Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy Diabetes Care 26 2003 1540 1544
18. W.T. Friedwald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clinical Chemistry 18 1972 499 502
19. A. Garg, and S.M. Grundy Management of dyslipidemia in NIDDM Diabetes Care 13 1990 153 169
20. D. Gaudet, D.J. Kereiakes, J.M. McKenney, E.M. Roth, C. Hanotin, and D. Gipe E.A. Stein Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) American Journal of Cardiology 114 2014 711 715
21. C. Gazzaruso, R. Bruno, A. Pujia, E. De Amici, P. Fratino, S.B. Solerte, and A. Garzaniti Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients International Journal of Cardiology 108 2006 354 358
22. P. Gillery, P. Arthuis, C. Cuperlier, and R.A. Circaud Peak-rate nephelometric assay of serum lipoprotein(a) Clinical Chemistry 39 1993 1122 1123
23. S.M. Haffner, and American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 Suppl. 1 2004 S68 S71
24. H.W. Hahmann, D. Schatzer-Klotz, T. Bunte, D. Becker, and H.J. Schieffer The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: Differences between men and women Atherosclerosis 144 1999 221 228
25. J.D. Horton, J.A. Cuthbert, and D.K. Spady Dietary fatty acids regulate hepatic low density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels Journal of Clinical Investigation 92 1993 743 749
26. B.V. Howard Lipoprotein metabolism in diabetes mellitus Journal of Lipid Research 28 1978 613 628
27. B.V. Howard, W.G. Abbott, W.F. Beltz, I.T. Harper, R.M. Fields, S.M. Grundy, and M.R. Taskien Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non- insulin-dependent diabetes Metabolism 36 1987 870 877
28. F. Kronenberg, and G. Utermann Lipoprotein (a): Resurrected by genetics Journal of Internal Medicine 273 2012 6 30
29. T.A. Lagace, D.E. Curtis, R. Garuti, M.C. McNutt, S.W. Park, and H.B. Prather J.D. Horton Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice Journal of Clinical Investigation 116 11 2006 2995 3005
30. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels Journal of Clinical Endocrinology & Metabolism 94 7 2009 2537 2543
31. G. Lambert Unravelling the functional significance of PCSK9 Current Opinion in Lipidology 18 2007 304 309
32. M.B. Lanktree, C. Rajakumar, J.H. Brunt, M.L. Koschinsky, P.W. Connelly, and R.A. Hegele Determination of lipoprotein (a) kringle repeat number from genomic DNA: Copy number variation genotyping using qPCR Journal of Lipid Research 50 4 2009 768 772
33. R.M. Lawn, N.W. Boonmark, K. Schwartz, G.E. Lindahl, D.P. Wade, and C.D. Byrne L. Patthy The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a) Journal of Biological Chemistry 270 1995 24004 24009
34. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy Journal of the American College of Cardiology 59 2012 2344 2353
35. J.Y. Moon, H.M. Kwon, S.W. Kwon, S.J. Yoon, J.S. Kim, and S.J. Lee H.S. Kim Lipoprotein (a) and LDL particle size are related to the severity of coronary artery disease Cardiology 108 2007 282 289
36. Q. Qi, L. Liang, A. Doria, F.B. Hu, and L. Qi Genetic pre-disposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts Diabetes 61 3 2012 745 752
37. F.L. Raal, R.P. Giugliano, M.S. Sabatine, M.J. Koren, G. Langslet, and H. Bays E.A. Stein Reduction in lipoprotein(a) with PCSK9 monoclonal antibody Evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phases II trials Journal of the American College of Cardiology 63 13 2014 1278 1288
38. C.K. Roberts, K. Liang, R.J. Barnard, C.H. Kim, and N.D. Vaziri HMG-CoA reductase, cholesterol 7a-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X Kidney International 66 4 2004 1503 1511
39. R. Romagnuolo, C.A. Scipione, M.B. Boffa, S.M. Marcovina, N.G. Seidah, and M.L. Koschinsky Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor Journal of Biological Chemistry 290 18 2015 11649 11662
40. A. Roubtsova, M.N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, and C. Lazure A. Prat Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arteriosclerosis, Thrombosis, and Vascular Biology 31 2011 785 791
41. D.J. Shin, and T.F. Osborne Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2) Journal of Biological Chemistry 278 2003 34114 34118
42. M. Smaoui, S. Hammami, R. Chaaba, N. Attia, K.B. Hamda, and A.S. Masmoudi M. Hammami Lipids and lipoprotein (a) concentration in Tunisian type 2 diabetic patients relationship to glycaemic control and coronary heart disease Journal of Diabetes and its Complications 18 2004 258 263
43. A. Sniderman, M. McQueen, J. Contois, K. Williams, and C.D. Furberg Why is non-high density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? Journal of Clinical Lipidology 4 2010 152 155
44. T. Suzuki, S. Futami-Suda, Y. Igari, K. Watanabe, M. Ouchi, and K. Suzuki K. Oba Low-molecular-weight lipoprotein (a) and low relative lymphocyte concentration are significant and independent risk factors for coronary heart disease in patients with type 2 diabetes mellitus: Lp(a) phenotype, lymphocyte, and coronary heart disease Lipids in Health and Disease 12 2013 31 37
45. W. Terres, E. Tatsis, B. Pfalzer, F.U. Beil, U. Beisiegel, and C.W. Hamm Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) Circulation 91 1995 948 950
46. The Expert Committee on the Diagnosis, and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 1997 1183 1197
47. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Arch Intern Med 157 1997 2413 2446
48. G. Utermann The mysteries of lipoprotein(a) Science 246 1989 904 910
49. P. Uusimaa, K. Kervinen, A. Kesaniemi, and K. Peukurinen Serum lipoprotein(a) level in relation to severity of coronary artery disease and coronary artery patency in acute myocardial infarction Heart and Vessels 16 2002 37 41
50. B. Vergès Lipid modification in type 2 diabetes: The role of LDL and HDL Fundamental & Clinical Pharmacology 23 2009 681 685
51. B. Vergès, L. Duvillard, M.C. Brindisi, E. Gautier, M. Krempf, P. Costet, and B. Cariou Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes Atherosclerosis 219 2011 342 348
52. G.F. Watts, R.M. Gwilym, J. Mazurkiewicz, and J. Coltart Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM Diabetes Care 18 1995 234 236
53. G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, and R.J. Konrad High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Journal of Lipid Research 51 2010 2714 2721
54. A. Zaid, A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, and J. Hamelin A. Prat Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 2 2008 646 654